Hester Biosciences Limited

NSE:HESTERBIO.NS

2567.45 (INR) • At close November 12, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 3,045.462,660.912,350.062,143.321,832.6841,780.6681,359.3861,231.0871,008.922906.352690.484651.043482.634419.714375.323301.6326.337218.279
Cost of Revenue 1,771.81774.86688.55563.93482.03524.142434.101295.91195.522380.976230.009247.751161.889176.632155.758111.098101.54797.153
Gross Profit 1,273.651,886.051,661.511,579.391,350.6541,256.526925.285935.177813.4525.376460.474403.291320.745243.082219.564190.501224.789121.126
Gross Profit Ratio 0.4180.7090.7070.7370.7370.7060.6810.760.8060.580.6670.6190.6650.5790.5850.6320.6890.555
Reseach & Development Expenses 46.6533.94010.2424.04531.74228.77528.33741.12532.0421.195.949000000
General & Administrative Expenses 49.0253.2374.1559.57115.15670.18768.23300021.86921.62866.0258.89448.65247.28245.00936.873
Selling & Marketing Expenses 256.04263.41173.11150.22227.189177.64107.1530073.16549.72243.835000000
SG&A 908.84316.64247.26209.79342.345247.827175.387188.511148.19273.16549.72243.83566.0258.89448.65247.28245.00936.873
Other Expenses 106.38151.515.5610.529.158.58514.1450.0380.0260.0490.4380.183107.47647.07351.28832.81944.138-3.046
Operating Expenses 908.841,586.911,096.78991.79879.361631.866529.588581.228533.607335.814266.432228.5173.496105.96899.9480.10189.14733.828
Operating Income 364.81420.28550.43591.22468.59625.781395.697307.854243.313169.837133.47144.065147.25137.114119.624110.4135.64287.298
Operating Income Ratio 0.120.1580.2340.2760.2560.3510.2910.250.2410.1870.1930.2210.3050.3270.3190.3660.4160.4
Total Other Income Expenses Net -45.24-880.31-717.38-66.81-46.791.628-18.6-35.313-32.303-289.402-63.883-33.354-28.28120.933-23.625-28.877-26.549-7.938
Income Before Tax 273.44401.54535.02501.03413.262568.561361.219307.854243.313169.837133.679144.065118.969111.83895.99981.522109.09379.361
Income Before Tax Ratio 0.090.1510.2280.2340.2250.3190.2660.250.2410.1870.1940.2210.2470.2660.2560.270.3340.364
Income Tax Expense 107.87121.19140.18154.05103.237161.625130.54480.95456.26348.17442.03353.36744.10644.12229.35118.88233.31410.512
Net Income 188.89266.27393.2344.3291.71415.673256.21234.483188.829124.65894.53792.59376.08575.9660.33247.36370.40751.513
Net Income Ratio 0.0620.10.1670.1610.1590.2330.1880.190.1870.1380.1370.1420.1580.1810.1610.1570.2160.236
EPS 24.8831.346.2240.4734.2948.8630.1227.6822.571611.1112.858.9907.756.089.047.43
EPS Diluted 24.8831.346.2240.4734.2948.8630.1227.6822.571611.1112.858.9907.756.089.047.43
EBITDA 539.47619.2731.93700.21617.68752.453498.174414.345340.12251.842254.151219.366188.484181.894161.959148.837172.48889.113
EBITDA Ratio 0.1760.2640.3170.3430.3350.420.3720.340.3360.270.3570.3360.3910.4330.4320.4930.5290.416